Searchable abstracts of presentations at key conferences in endocrinology

ea0035p537 | Endocrine tumours and neoplasia | ECE2014

Sunitinib induced hypocalcaemia during treatment of pancreatic neuroendocrine tumours

Alexandraki Krystallenia , Karnezis James , Kaltsatou Maria , Chatzellis Eleftherios , Tsoli Marina , Chrysochoou Maria , Boutzios Georgios , Kaltsas Gregory

Background: Although sunitinib, an oral multitargeted tyrosine kinase inhibitor of RET, VEGFR, PDGFR, c-KIT used for cancer treatment, has a reported prevalence of hypocalcemia of 35%, this has not been documented in pancreatic neuroendocrine tumour (pNETs).Methods: We present three, out of 12, patients with pNETs treated with sunitinib who developed grade 1, 2 and 4 hypocalcemia according Common Terminology Criteria for Adverse Events v3.0 (CTCAE) crite...

ea0041ep633 | Endocrine tumours and neoplasia | ECE2016

Mechano growth factor (MGF) expression increased in secondary compared to primary foci in well neuroendocrine neoplasms

Alexandraki Krystallenia , Philippou Anastasios , Boutzios Georgios , Moschouris Panagiotis , Karnezis James , Theohari Irini , Koutsilieris Michael , Delladetsima Ioanna , Kaltsas Gregory

Introduction: Insulin-like growth factor-I (IGF-I) has a role in cell proliferation, differentiation, migration, and survival. By alternative splicing different IGF-I mRNA transcripts as IGF-IEc (mechano growth factor, MGF) or IGF-IEa variants are produced. MGF induces muscle hypertrophy and implicated in the pathophysiology of various types of cancer. Aim of the study was to investigate the role of MGF in the pathophysiology of neuroendocrine neoplasms (NENs).<p class="ab...